UT Arlington researchers are exploring a better method for initiating certain gene therapies that could better fight the sight-deteriorating disease retinitis pigmentosa.
The National Institutes of Health is funding the research.
Samarendra Mohanty, assistant professor of physics, expects to receive a total of $384,269 over the next two years from the NIH’s National Institute of Neurological Disorders and Stroke. His work involves using near-infrared ultrafast laser beam to deliver genes that allow expression of light-sensitive proteins, called opsins, in specific cells. That proteins’ expression allows researchers to influence neural activity through optical or light stimulation - a technique known as optogenetics.
In the past, the genes have been delivered to cells by virus. That method can have drawbacks, such as immune responses, in addition to the benefits. In Mohanty’s method, a laser beam creates a transient sub-micrometer size hole, which allows for the gene encoding the proteins to permeate through the cell membrane. It can limit the risk of immune response, as well as delivering larger genes than viral methods, he said.
Digant Dave, an associate professor of bioengineering at UT Arlington, is the co-investigator on the new grant.
“Our minimally invasive near-infrared method can deliver DNA and other impermeable molecules effectively where you want it and only where you want it,” Mohanty said. “For example, in retinitis pigmentosa, only peripheral retina begins to lose light sensitivity due to loss of photoreceptors. This is where a laser can deliver the genes, making those neurons respond to light again. With a virus, the genes will be delivered everywhere, causing